Novartis Discontinues Lung Cancer Drug Development

14 November 2010 (Last Updated November 14th, 2010 18:30)

Novartis has discontinued a Phase III clinical trial programme of investigational lung cancer treatment ASA404 (vadimezan), following interim study results that indicated the drug was not likely to meet the trial's primary endpoint. The Phase III trial evaluated ASA404 in combination w

Novartis has discontinued a Phase III clinical trial programme of investigational lung cancer treatment ASA404 (vadimezan), following interim study results that indicated the drug was not likely to meet the trial's primary endpoint.

The Phase III trial evaluated ASA404 in combination with chemotherapy as second-line treatment for patients with non-small cell lung cancer, with a primary endpoint to prolong overall survival.

An independent data monitoring committee recommended the discontinuation of the trial, and the company has notified the study investigators and regulatory agencies of the decision.

Novartis has said that the resources will be reallocated to other compounds in its oncology pipeline.